The Report Obesity Therapeutics to 2019 – Safety Concerns. – MarketResearchReports.biz „
GBI Research, the leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns, Drug Performance Without Large Market Opportunity. Obesity is often described as a global endemic, with incidence. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes
View Report At http://www.marketresearchreports.biz/analysis/173940
Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), depression and cardiovascular problems with their long-term use. As a healthcare provider, it is important to be aware of the risks associated with the disease. Only orlistat is currently safe for the long-term treatment of obesity; To be able to produce a weight of 3kg. Two anti-obesity drugs were approved in June and July, 2012, and GBI Research believes that only one, Vivus‘ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make A Significant impact on the market, it is proven safe in long-term use studies.
If proven safe, GBI Research expects the sales of Qsymia and other drugs. Although moderate, this is significantly below the market potential given the size of the prevalence population. If you are looking for an alternative medicine, you may want to consider the benefits of obesity.
Download sample copy of this report at: http://www.marketresearchreports.biz/sample/sample/173940
Scope
The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and anti-obesity drugs.
The report includes:
A brief introduction to obesity; Detailed analysis of recent, current and projected incidence trends; Co-morbidities; Economic implications of their treatment; And the current treatment options
Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance
Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action
Statistical analysis of clinical trial duration, size, and failure rate by phase and molecule type
An in-depth forecast model for the anti-obesity drug market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of branded drugs.
A detailed discussion of the drivers and barriers for this immature market
Reasons to Buy
The report will enhance your decision-making capability by allowing you to:
Understand the large number of potential molecular targets for the development of anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type
Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development
Observe the trends in clinical trials by the end of the year
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market
Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and depth details of the highest value deals
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Etiology and Pathophysiology
2.2 Classification
2.3 Epidemiology
2.3.1 The US
2.3.2 Obesity in the Top Five European Markets
2.3.3 Japan
2.4 Comorbidities
2.4.1 Type 2 diabetes
2.4.2 Hypertension
2.4.3 Dyslipidemia
2.4.4 Respiratory Problem
2.4.5 Osteoarthritis
2.4.6 Cancer Risk
2.5 Economic Burden
2.6 Current Therapy Options
2.6.1 Lifestyle and Behavioral Modifications
2.6.2 Bariatric Surgery
2.6.3 Pharmacotherapy
2.6.4 Treatment Algorithms and Prescription Habits
2.6.5 Method of Determining Treatment Effectiveness
2.7 Why Develop Therapeutic Anti-Obesity Drugs?
2.8 GBI Research Report Guidance
3 Branded Products
3.1 Amphetamine-like Drugs
3.1.1 Overview
3.1.2 Efficacy profiles
3.1.3 Safety profiles
3.2 Qsymia, Vivus, Inc.
3.2.1 Overview
3.2.2 Efficacy profiles
3.2.3 Safety profiles
3.2.4 Discussion
3.3 Orlistat
3.3.1 Overview
3.3.2 Efficacy profiles
3.3.3 Safety profiles
3.3.4 Discussion
3.4 Belviq, Arena Pharmaceuticals
3.4.1 Introduction
3.4.2 Efficacy profiles
3.4.3 Safety profiles
3.4.4 Discussion
3.5 Low Long-term Success Rate of Branded Anti-Obesity Drugs
3.6 Discussion
4 Pipeline
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target
4.2 Clinical Trial Duration and Size
4.2.1 Clinical Trial Duration
4.2.2 Clinical Trial Size
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure
4.4 Primary and Secondary Endpoints
4.5 Late-stage Drugs of the Developmental Pipeline
4.5.1 Contrave, Orexigen Therapeutics
4.5.2 Cametor, Norgine BV
4.5.3 Victoza, Novo Nordisk
4.5.4 Tesofensine (NeuroSearch)
4.6 Discussion
5 Market Forecasts
5.1 Global Market
5.2 The US
5.2.1 Epidemiology and Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Europe
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one-stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: + 1-518-621-2074